Laboratorios Jayor will invest US$19.3 million to expand its plant in Pilar
Laboratorios Jayor is investing US$19.3 million to expand its manufacturing plant in Pilar, Argentina, which will include a new production line and increase capacity by 50%.
European Union willing to accept that Trump imposes tariffs... with one condition
The European Union is open to a trade agreement with the U.S. that includes a universal 10% tariff on many exports, provided the U.S. lowers tariffs on key sectors such as pharmaceuticals and aircraft.
When the pantry was the first pharmacy
The article discusses the historical connection between food and medicine, emphasizing the therapeutic roles of everyday ingredients before the advent of modern pharmaceuticals.
Will drugs from China flood Europe? "A serious threat to pharmaceutical safety"
Polish pharmaceutical industry leaders express concerns over the increasing reliance on Chinese-produced active pharmaceutical ingredients (APIs), warning it poses a significant threat to the security of medication supplies in Europe.
Mazdutide, the 'miracle' injection to lose up to 15% of weight created by China
A new obesity medication, Mazdutide, developed by China’s Innovent Biologics and Eli Lilly, has shown significant weight loss results and is on track for approval in China.
New oral GLP-1 reduces more glucose and weight than semaglutide in phase 3 study; Orforgliprona increases weight loss by 73%
The experimental drug orforgliprona demonstrated greater glucose control and weight loss compared to oral semaglutide in a phase 3 study for type 2 diabetes treatment.
Asahi Kasei to Acquire German Pharmaceutical Company, With Over 100 Billion Yen in Recent Acquisitions
Asahi Kasei has announced its acquisition of the German pharmaceutical development company Aiquiris for approximately €780 million, marking its third acquisition in the pharmaceutical sector since 2020.
It is time to overcome spending ceilings
The president of Farmindustria, Marcello Cattani, defends the growth of healthcare spending in Italy, attributing it to innovation while calling for a balanced discussion free of recent controversies.
Robots and People Working in the Giant Warehouse of Magnum, Whose Decisions May Depend on Someone's Life
The article discusses an initiative aimed at educating children about various professions, particularly in the field of medicine, through workplace visits.
Brazilian pharmaceutical companies seek Indian technology for weight loss pen manufacturing
Brazilian pharmaceutical firms Biomm and Amoveri are pursuing Indian technology agreements to produce weight loss pens ahead of the patent expiration for Ozempic in 2026.
The government provided investment incentives for the production of pharmaceuticals by Sabola and Világi and an Italian electrotechnical company
Slovakia's government approved significant tax incentives for Saneca Pharmaceuticals and Datalogic, aiming to create new jobs and expand production capabilities.
Pharmaceutical company Dr. Reddy's prepares to launch a cheap generic Ozempic in India in March
Indian pharmaceutical company Dr. Reddy’s Laboratories is set to launch a generic version of the diabetes drug Ozempic, named Obeda, in March 2026 following the expiration of the semaglutide patent.
Lula's government seeks to reduce the deficit of pharmaceutical inputs and technology in India
Brazil's President Lula da Silva is visiting India to address the country's significant deficit in pharmaceutical supplies, aiming to transfer technology to enhance the local healthcare industry.
Novo Nordisk: Reducing drug prices for obesity and diabetes by 50% in the USA
Novo Nordisk has announced a 50% reduction in the prices of its obesity and diabetes medications in the USA, effective January 2027.
The prices of Ozempic and Wegovy will drop by up to half – but not everyone will benefit
Novo Nordisk announced that the prices of popular weight loss drugs Ozempic and Wegovy will significantly decrease starting in 2027, with Wegovy becoming half as expensive and Ozempic a third less expensive for all patients.
The number of prescriptions for medical marijuana is once again on the rise. The Patient Rights Ombudsman responds
The rise in medical marijuana prescriptions follows a significant decline tied to upcoming legal changes in Poland that will require in-person patient evaluations.
Marketta was stunned: The price of the medicine rose by +400% - 'I have to use it'
Marketta, a 75-year-old Finnish woman, is shocked by the 400% price increase of her essential heart medication, now forcing her to pay significantly more.
AstraZeneca boss Pascal Soriot’s pay rises to £17.7m
Pascal Soriot, CEO of AstraZeneca, received a £17.7 million total remuneration, marking a 6.4% increase from the previous year, amid controversies regarding investment cuts in the UK.
Novo Nordisk Reduces List Price of Wegovy in the USA by Half
Novo Nordisk has announced a significant reduction in the list prices of its drugs, including Wegovy, Ozempic, and Rybelsus, effective January 2027.
The Competition Council has allowed 'Latvijas aptieka' to gain decisive influence over 'Farma Balt aptieka'
The Competition Council of Latvia has approved a merger allowing 'Latvijas aptieka' to gain significant influence over 'Farma Balt aptieka', with no adverse effects on market competition anticipated.
A fine of eight million was imposed for a cartel in pharmaceuticals, helped by a whistleblower for the first time
Two suppliers of expensive medications were fined for colluding to win competitions with a state health insurance company, aided by a whistleblower.
Novo Nordisk sinks again on the stock market after failing trials for its new obesity drug
Novo Nordisk's shares dropped significantly after the company reported failures in trials for its experimental obesity drug, CagriSema.
Business Ticker: Novo Nordisk shares fall by 11 percent – set back with weight loss drug
Novo Nordisk shares have dropped by 11 percent due to setbacks related to its weight loss medication.
Juan Toral Sánchez, specialist in Primary Care and Emergencies: "If sugar were discovered today, it would be classified as a food drug"
Juan Toral Sánchez critiques the food and pharmaceutical industries' influence on public health, suggesting they profit from perpetuating a culture of illness.
U.S. to impose temporary 10% tariff for 150 days starting on the 24th, excluding key minerals, cars, and pharmaceuticals
The U.S. will implement a temporary 10% tariff on imports for 150 days, which excludes key minerals, cars, and pharmaceuticals, starting from the 24th.
Medicine between the laboratory and the market: Who writes and funds medical studies?
The article discusses the skepticism surrounding the pharmaceutical and food industry funding of medical research and the evolution of medical research practices over the years.
Business Ticker: Trump: Novartis Builds Eleven Factories in the USA Due to Tariff Policy
Novartis announced plans to build eleven new factories in the USA, attributed to tariff policies advocated by President Trump.
Wait, Adamed: Finance in Pharmaceuticals? Between the Risk of Innovation and Capital Discipline
Dr. Karolina Czekaj emphasizes the evolving role of CFOs in the pharmaceutical sector, highlighting their strategic importance beyond just expense management.
OFET at WHX Dubai: Establishing Its Presence in the Middle East
The Pharmaceutical Enterprises Group Tsetis (OFET) is enhancing its presence in the Middle East by actively participating in major health expos, most notably the WHX Dubai.
New Major Deal in the Wholesale Pharmaceutical Market – Acquisition of Dynamic Pharmacy Warehouse by Profarm
Profarm announces the acquisition of Dynamic Pharmacy Warehouse, aiming to transform the wholesale market in Greece while maintaining the existing management and identity of Dynamic Pharmacy.
Review of the T-MEC: US denounces that Mexico is failing to meet intellectual property commitments in medicines
US organizations accuse Mexico of not adhering to intellectual property commitments under the T-MEC agreement, particularly regarding pharmaceuticals.
Pharmaceuticals say proposal to extend Ozempic patent pressures health spending
Pharmaceutical companies in Brazil criticize a proposal to extend the patent duration of medications, arguing it could increase healthcare costs and reduce access.
New concerns about weight loss drugs: What happens if they work... too well?
Recent trials involving the weight loss drug retatrutide have raised concerns after participants reported significant weight loss, but also higher than normal dropout rates due to side effects.
2.5 billion won rebate to medical professionals... corrective order to Dong Sung Pharmaceutical
Dong Sung Pharmaceutical has been sanctioned by the Fair Trade Commission for providing approximately 250 million won in illegal rebates to doctors in the Seoul metropolitan area over a nine-year period.
Pharma Scandal in the USA: Vaccination in Lordly Style
The article discusses the controversial handling of RNA vaccine testing for influenza by US authorities, criticized for being influenced by anti-vaccine sentiment within the government.
India: Generic versions of Ozempic and Wegony Coming – They Will Be 60% Cheaper
An Indian pharmaceutical company is set to launch generic versions of obesity drugs Ozempic and Wegony at significantly reduced prices in India.
The 'Perfect Drug' from AI? A New Therapy for Obesity Could Upset the Market
A new AI-discovered therapy for obesity, ISM0676, presents potential advantages over existing GLP-1 receptor agonists, signifying a major shift in obesity treatment.
The fastest-growing pharmaceutical companies invest in innovation
Greece's rapidly growing pharmaceutical sector is investing heavily in innovation, driven by strategic mergers, acquisitions, and access to the U.S. market.
Mergers and acquisitions are changing the landscape in the pharmaceutical industry
International and Greek pharmaceutical mergers and acquisitions are on the rise, focusing on innovative drugs and expiring patents.
The Developer of Ozempic's Bold Claim: This Plate Model is as Effective as Weight Loss Medication – 'The Body Can Do It Itself'
A former pharmaceutical executive claims that activating certain cells and hormones through a specific diet can be as effective for weight loss as taking Ozempic, a popular medication.
Weight loss pens expected to account for 20% of pharmacy revenue by 2030
Weight loss pens, specifically GLP-1 agonists like Ozempic and Mounjaro, are projected to represent 20% of the revenue of major pharmacy chains in Brazil by 2030.
Lilly bets on Spain to manufacture obesity pills: 'A new plant will allow us to quadruple the amount produced here'
Lilly, the American multinational, is investing 153 million euros in expanding its production plant in Alcobendas, Spain, to significantly increase its capacity for producing obesity treatment pills.
In Pernambuco, Lula visits factory that will supply medicines to the SUS
President Lula visited Aché Pharmaceuticals in Pernambuco, which is expanding to produce sterile medications for Brazil's public health system, the SUS.
China charges former AstraZeneca executive – what it means for global pharmaceutical firms
China has formally charged former AstraZeneca executive Leon Wang with multiple offenses, highlighting pressures facing foreign pharmaceutical companies in a tightening regulatory environment.
After Merck's exit: Belén Garijo takes over at the helm of Sanofi
Belén Garijo, the departing CEO of Merck, is set to lead the French pharmaceutical giant Sanofi following the sudden exit of its former CEO, Paul Hudson.
Legal Dispute Over Weight Loss Drugs: Ozempic Manufacturer Accuses Competitor of Selling Dangerous Product
Danish pharmaceutical company Novo Nordisk has sued American company Hims & Hers, accusing it of selling an 'unsafe' copy of its weight loss drug.
Pharmaceutical Industry: Merck CEO Garijo transfers to Sanofi
The French pharmaceutical company Sanofi unexpectedly replaces its CEO with Belén Garijo, previously at Merck, following Paul Hudson's departure.
Alzheimer's Disease, a New Study Identifies Harmful Plaques for the Brain
A new scientific study has discovered a protein's role in eliminating harmful plaques in the brains of Alzheimer's patients, potentially leading to new therapies.
Sanofi appoints Spanish Belén Garijo as new CEO to regain operational and stock market momentum
Sanofi has appointed Belén Garijo as its new CEO to address operational challenges and improve stock performance following the dismissal of Paul Hudson.
Pharmaceutical company Orion achieved strong results
Finnish pharmaceutical company Orion reported a 60% increase in revenue for Q4, significantly driven by the sales of its prostate cancer drug, Nubeqa.